Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gero Brockhoff

Showing results (11-20 of 85) with videos related to

Pageof 9
Sort By:
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|July 26, 2011
Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factorsSimone Diermeier-Daucher, Stefanie Breindl, Stefan Buchholz, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|April 21, 2015
Topotecan-induced ABCG2 expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicityStefan Huber, Anja K Wege, Günther Bernhardt, et al.
Cytometry|July 13, 2002
Flow cytometric detection of activated mouse integrin alphaIIbbeta3 with a novel monoclonal antibodyWolfgang Bergmeier, Valerie Schulte, Gero Brockhoff, et al.
Experimental Cell Research|March 8, 2005
Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activationSimone Diermeier, Gábor Horváth, Ruth Knuechel-Clarke, et al.
International Journal of Oncology|May 11, 2006
Effective silencing of EGFR with RNAi demonstrates non-EGFR dependent proliferation of glioma cellsArabel Vollmann, Hans-Peter Vornlocher, Thomas Stempfl, et al.
Oncotarget|November 12, 2016
IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM)Anja K Wege, Florian Weber, Alexander Kroemer, et al.
BMC Cancer|June 1, 2025
Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibitionAlina Goerg, Gerhard Piendl, Veruschka Albert, et al.
Analytical and Quantitative Cytology and Histology|August 13, 2010
EGFR (HER) family protein expression and cytogenetics in 219 squamous cell carcinomas of the upper respiratory tract: ERBB2 overexpression independent prediction of poor prognosisKathrin Brunner, Claude A Fischer, Oliver Driemel, et al.
BMC Cancer|September 26, 2013
The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patientsAnna Machleidt, Stefan Buchholz, Simone Diermeier-Daucher, et al.
The Journal of Pathology|February 26, 2005
Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancerChristian Lottner, Stephan Schwarz, Simone Diermeier, et al.
Pageof 9

Showing results (11-20 of 85) with videos related to

Sort By:
Pageof 9
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|July 26, 2011
Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factorsSimone Diermeier-Daucher, Stefanie Breindl, Stefan Buchholz, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|April 21, 2015
Topotecan-induced ABCG2 expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicityStefan Huber, Anja K Wege, Günther Bernhardt, et al.
Cytometry|July 13, 2002
Flow cytometric detection of activated mouse integrin alphaIIbbeta3 with a novel monoclonal antibodyWolfgang Bergmeier, Valerie Schulte, Gero Brockhoff, et al.
Experimental Cell Research|March 8, 2005
Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activationSimone Diermeier, Gábor Horváth, Ruth Knuechel-Clarke, et al.
International Journal of Oncology|May 11, 2006
Effective silencing of EGFR with RNAi demonstrates non-EGFR dependent proliferation of glioma cellsArabel Vollmann, Hans-Peter Vornlocher, Thomas Stempfl, et al.
Oncotarget|November 12, 2016
IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM)Anja K Wege, Florian Weber, Alexander Kroemer, et al.
BMC Cancer|June 1, 2025
Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibitionAlina Goerg, Gerhard Piendl, Veruschka Albert, et al.
Analytical and Quantitative Cytology and Histology|August 13, 2010
EGFR (HER) family protein expression and cytogenetics in 219 squamous cell carcinomas of the upper respiratory tract: ERBB2 overexpression independent prediction of poor prognosisKathrin Brunner, Claude A Fischer, Oliver Driemel, et al.
BMC Cancer|September 26, 2013
The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patientsAnna Machleidt, Stefan Buchholz, Simone Diermeier-Daucher, et al.
The Journal of Pathology|February 26, 2005
Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancerChristian Lottner, Stephan Schwarz, Simone Diermeier, et al.
Pageof 9